UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsDowngradesPrice Target
UBS analyst A.J. Rice downgrades Surgery Partners (NASDAQ:SGRY) from Buy to Neutral and raises the price target from $21 to $23.5.
UBS analyst A.J. Rice downgrades Surgery Partners (NASDAQ:SGRY) from Buy to Neutral and raises the price target from $21 to $23.5.